Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

Abe, Masanori; Kikuchi, Fumito; Okada, Kazuyoshi; Kaizu, Kazo; Matsumoto, Koichí

doi:10.1016/j.diabres.2008.01.028

Cited by 13 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, whether because of the increasing prevalence of diabetes or more frequent creatinine testing, the number of included people with diabetes and CKD increased over the period of study . Second, although pioglitazone may decrease the risk of cardiovascular events in people with CKD and thiazolidinedione therapy can be used in this population , there has been a decline in prescriptions for these agents over time. This finding may be attributable to safety concerns that have arisen with the use of these medications, and to changes in their funding status that took place in the province of Ontario in 2009 .…”

Section: Discussionmentioning

confidence: 99%

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013

Clemens

Liu

Shariff

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013

Clemens

Liu

Shariff

et al. 2016

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…Total, free, and acyl carnitine measurements were entrusted to Bio-Medical Laboratories, Inc. (Tokyo, Japan), and measured by enzyme cycling methods. Insulin resistance was assessed using plasma immunoreactive insulin (IRI) and homeostasis model assessment for insulin resistance (HOMA-R), with HOMA-R = fasting glucose (mg/dl) × fasting IRI (mU/ml)/405 [ 7 ].…”

Section: Methodsmentioning

confidence: 99%

L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients

Irie

Kanno

Kikuchi

et al. 2017

Bioscience of Microbiota, Food and Health

View full text Add to dashboard Cite

Patients receiving hemodialysis also manifest gastrointestinal symptoms, such as constipation, caused by restriction of water intake and the loss of body water balance. Because dietary carnitine deficiency is considered to cause smooth muscle dysmotility of the gastrointestinal tract similarly to that in skeletal muscles, carnitine deficiency in hemodialysis patients may be one cause of gastrointestinal discomfort and dysfunctions. We performed a multicenter nonrandomized single-arm prospective clinical trial. Fifteen Japanese patients receiving hemodialysis were administered L-carnitine tablets (900 mg) for 3 months, and clinical and biochemical analyses were performed before and after treatment. The serum total carnitine level was increased significantly by supplementation with L-carnitine for 3 months (from 40.9 ± 2.6 μmol/l to 172.3 ± 19.0 μmol/l, p<0.05). The myasthenia score was decreased significantly by the supplementation (from 1.3 ± 0.3 to 0.8 ± 0.2, p<0.05). The frequency of passing stool tended to increase with the treatment for 3 months (from 4.2 ± 0.5 times/week to 4.8 ± 0.5 times/week). A phyla-level analysis of the microbiota showed that the composition of the individual microbiota was not different between before and after supplementation. A genus-level analysis, however, revealed that the relative abundance of genus Clostridium subcluster 4 was significantly decreased by the supplementation (from 7.7 ± 1.9% to 4.7 ± 1.3%, p<0.05). Oral supplementation of L-carnitine to the patients receiving hemodialysis improved not only their muscle discomfort but also their gastrointestinal disorders and microbiota, although its effect on the prognosis of hemodialysis patients should be further investigated.

show abstract

“…When the responder was defined as decrease of HbA1c ≥ 1.0% for 6 months on pioglitazone up- Until now, only one study reported the efficacy and safety of pioglitazone according to dose up-titration, which examined the effects of an increased dose of pioglitazone from 15 to 30 mg/day on its glucoselowering efficacy in Japanese diabetes patients undergoing hemodialysis [12]. In that study, the patients were administered pioglitazone 15 mg daily with their morning meal for the first 4 weeks.…”

Section: Determinants For Responders (Table 2 and 3)mentioning

confidence: 99%

Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone

Jung

Choi

et al. 2016

J Korean Diabetes

View full text Add to dashboard Cite

Background:The 30 mg pioglitazone tablet was recently introduced in Korea; no study has yet compared its glucose-lowering or weight gain effects to the 15 mg tablet in Korean patients with type 2 diabetes mellitus (T2DM). Methods: The electronic medical records of 45 patients with T2DM with glycated hemoglobin (HbA1c) levels > 7.0%, despite taking 15 mg/day pioglitazone and a stable dose of other diabetes drugs for 3 months, were retrospectively reviewed. Results: After dose up-titration, HbA1c levels decreased at 3-and 6-month follow-ups compared with baseline (8.5% at baseline vs. 8.2% at 3 months vs. 7.9% at 6 months; baseline vs. 3 months, P = 0.106; baseline vs. 6 months, P = 0.005; 3 months vs. 6 months, P = 0.096). In the subgroup analysis of 36 patients taking pioglitazone, sulfonylurea, and metformin, HbA1c levels also decreased at 3-and 6-month follow-ups compared with baseline (8.5 % vs. 8.2 % vs. 7.9%; baseline vs. 3 months, P = 0.289; baseline vs. 6 months, P = 0.014; 3 months vs. 6 months, P = 0.232). There was no significant body weight change (70.8 kg vs. 70.7 kg vs. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis

Cited by 13 publications

References 28 publications

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013

Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013

L-Carnitine improves gastrointestinal disorders and altered the intestinal microbiota in hemodialysis patients

Retrospective Observational Dose-Titration Study of Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on 15 mg of Pioglitazone

Contact Info

Product

Resources

About